How big is Sarepta Therapeutics, Inc.?

As of Jun 18, Sarepta Therapeutics, Inc. has a market capitalization of $2.12 billion, with net sales of $2.23 billion and a net profit of -$248.39 million over the last four quarters.

Market Cap: As of Jun 18, Sarepta Therapeutics, Inc. has a market capitalization of 2,118.85 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Sarepta Therapeutics, Inc. reported net sales of 2,233.37 million and a net profit of -248.39 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company had shareholder's funds amounting to 1,527.74 million and total assets of 3,963.17 million.

What does Sarepta Therapeutics, Inc. do?

Sarepta Therapeutics, Inc. is a biopharmaceutical company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. As of March 2025, it reported net sales of $745 million and a net loss of $448 million, with a market cap of approximately $2.12 billion.

Overview:<BR>Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics for rare neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD), and operates within the Pharmaceuticals & Biotechnology industry in the mid-cap market segment.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 745 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -448 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 2,118.85 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.54<BR>- Return on Equity: -13.99%<BR>- Price to Book: 1.85<BR><BR>Contact Details:<BR>- Address: 215 1st St Ste 415, CAMBRIDGE MA: 02142-1213<BR>- Tel: 1 617 2744000<BR>- Website: https://www.sarepta.com/

Should I buy, sell or hold Sarepta Therapeutics, Inc.?

Who are in the management team of Sarepta Therapeutics, Inc.?

As of March 2022, the management team of Sarepta Therapeutics, Inc. includes Dr. M. Kathleen Behrens (Independent Chairwoman), Mr. Douglas Ingram (President and CEO), and several Independent Directors: Mr. Richard Barry, Dr. Mary Gray, Dr. John Martin, Dr. Claude Nicaise, and Dr. Hans Wigzell. They are responsible for guiding the company's strategic direction.

As of March 2022, the management team of Sarepta Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. M. Kathleen Behrens, who serves as the Independent Chairwoman of the Board.<BR>- Mr. Douglas Ingram, who is the President, Chief Executive Officer, and Director.<BR>- The Board of Directors also includes Independent Directors: Mr. Richard Barry, Dr. Mary Gray, Dr. John Martin, Dr. Claude Nicaise, and Dr. Hans Wigzell.<BR><BR>This team plays a crucial role in guiding the strategic direction of the company.

Is Sarepta Therapeutics, Inc. overvalued or undervalued?

As of May 6, 2025, Sarepta Therapeutics, Inc. is considered risky and overvalued, with concerning valuation metrics and a year-to-date stock performance decline of 84.77%, significantly underperforming the S&P 500's 12.22% gain.

As of 6 May 2025, the valuation grade for Sarepta Therapeutics, Inc. has moved from attractive to risky, indicating a significant deterioration in its valuation outlook. The company is currently overvalued, as evidenced by its Price to Book Value of 3.70 and an EV to Sales ratio of 2.17, both of which suggest that the stock is trading at a premium compared to its underlying assets and revenue generation capabilities. Additionally, the negative EV to EBITDA of -77.97 highlights the challenges the company faces in generating positive earnings before interest, taxes, depreciation, and amortization.<BR><BR>In comparison to its peers, Sarepta's valuation metrics are concerning; for instance, Viatris, Inc. has a P/E ratio of 44.86, while Walgreens Boots Alliance, Inc. shows a P/E of -14.12, both indicating a more favorable valuation relative to their earnings. Furthermore, Sarepta's recent stock performance has been dismal, with a year-to-date return of -84.77% compared to the S&P 500's gain of 12.22%, underscoring the disconnect between its current valuation and market sentiment.

Is Sarepta Therapeutics, Inc. technically bullish or bearish?

As of August 12, 2025, Sarepta Therapeutics, Inc. is in a mildly bearish trend, with mixed technical indicators showing underperformance of -84.77% year-to-date compared to the S&P 500's 12.22% return.

As of 12 August 2025, the technical trend for Sarepta Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The RSI is bullish monthly but shows no signal weekly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, Bollinger Bands and KST are both mildly bearish on the weekly and monthly timeframes, while OBV is mildly bullish monthly but mildly bearish weekly. <BR><BR>In terms of performance, Sarepta has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -84.77% versus the S&P 500's 12.22%.